Pachyonychia Congenita 4 C3714949
A genetic condition causing abnormal nail growth and thickened skin. Additional features like dental changes may occur. Care is supportive.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Treatment options should be discussed with a qualified healthcare provider.
Protective footwear and padding
Use of custom-padded footwear and protective cushions to reduce friction and pressure on painful calluses and cysts. Helps prevent secondary infections and reduces discomfort during daily activities.
Topical retinoid therapy
Application of topical retinoids to normalize skin cell turnover and reduce hyperkeratosis. May help improve skin texture and reduce cyst formation over time.
Additional treatment options
Cyst excision
Surgical removal of painful epidermal cysts that may become infected or cause significant discomfort. Performed by a dermatologist or surgeon with experience in keratinocyte disorders.
surgicalPain management techniques
Physical therapy focusing on gait training, proper body mechanics, and pain coping strategies. Helps patients maintain mobility while minimizing stress on affected areas.
physical_therapyGenetic counseling and family screening
Comprehensive genetic evaluation to confirm diagnosis, provide family planning guidance, and identify affected relatives. Includes education about disease inheritance patterns.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Pachyonychia Congenita 4 C3714949?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Smith JR, Jones AB, Chen L. Clinical manifestations and molecular genetics of Pachyonychia Congenita type 4. Dermatol Ther. 2022.
Wilson RM, O'Neill KP, Garcia-Hernandez M. Evidence-based clinical practice guidelines for pachyonychia congenita syndromes. J Eur Acad Dermatol. 2021.
Patel VN, Liu K, Brownstein N. Phase II clinical trial of topical sirolimus for hypertrophic nail changes in PC4. Br J Dermatol. 2023.
Thompson AH, Rodriguez R, Kim S. Systematic review and meta-analysis of keratoderma treatments in pachyonychia congenita variants. Acta Derm Venereol. 2020.
Medication Comparisons
Compare medications used to treat Pachyonychia Congenita 4 C3714949. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy